TY - JOUR
T1 - Outcome Evaluation of HER2 Breast Cancer Patients with Limited Brain Metastasis
AU - Pessina, Federico
AU - Navarria, Pierina
AU - Cozzi, Luca
AU - Franceschini, Davide
AU - Tomatis, Stefano
AU - Clerici, Elena
AU - Ascolese, Anna Maria
AU - DE Rose, Fiorenza
AU - Bello, Lorenzo
AU - Masci, Giovanna
AU - Santoro, Armando
AU - Scorsetti, Marta
PY - 2017/12/1
Y1 - 2017/12/1
N2 - BACKGROUND/AIM: To appraise the outcome of limited brain metastasis (BMs) from HER2 breast cancer.PATIENTS AND METHODS: The study cohort included sixty-six patients Treatments consisted of surgery followed by radiotherapy (RT), or radiosurgery (SRS/HSRS) or whole brain radiotherapy (WBRT).RESULTS: Surgery followed by RT was performed in 25.8% of patients, SRS/HSRS alone in 48.5%, and WBRT alone in 25.7%. The median follow-up time was 23.4 months and 32.5 months for alive patients. Local recurrence occurred in 16 (24.2%) patients. The median, 1-, 2-, 3-year local control were (median not reached=nr), 87.5%, 71.2%, and 63.0%. The median 1-, 2-, 3-year overall survival were 30.7 months (95%CI: 18.9-42.6 months), 78.5%, 57.4%, 43.3%. Karnofsky Performance Scale (KPS), number of BMs, local treatment performed, the presence of extracranial (EC) metastases at the time of BMs diagnosis, and the administration of trastuzumab affected survival.CONCLUSION: HER2BC patients with good performance status, controlled EC disease and single BM had better outcome. In this long-term survivor patients, local BMs treatment can affect survival.
AB - BACKGROUND/AIM: To appraise the outcome of limited brain metastasis (BMs) from HER2 breast cancer.PATIENTS AND METHODS: The study cohort included sixty-six patients Treatments consisted of surgery followed by radiotherapy (RT), or radiosurgery (SRS/HSRS) or whole brain radiotherapy (WBRT).RESULTS: Surgery followed by RT was performed in 25.8% of patients, SRS/HSRS alone in 48.5%, and WBRT alone in 25.7%. The median follow-up time was 23.4 months and 32.5 months for alive patients. Local recurrence occurred in 16 (24.2%) patients. The median, 1-, 2-, 3-year local control were (median not reached=nr), 87.5%, 71.2%, and 63.0%. The median 1-, 2-, 3-year overall survival were 30.7 months (95%CI: 18.9-42.6 months), 78.5%, 57.4%, 43.3%. Karnofsky Performance Scale (KPS), number of BMs, local treatment performed, the presence of extracranial (EC) metastases at the time of BMs diagnosis, and the administration of trastuzumab affected survival.CONCLUSION: HER2BC patients with good performance status, controlled EC disease and single BM had better outcome. In this long-term survivor patients, local BMs treatment can affect survival.
KW - Brain metastases
KW - radiosurgery
KW - surgery
KW - targeted therapy
UR - http://www.scopus.com/inward/record.url?scp=85038129884&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85038129884&partnerID=8YFLogxK
M3 - Article
C2 - 29187495
AN - SCOPUS:85038129884
VL - 37
SP - 7057
EP - 7062
JO - Anticancer Research
JF - Anticancer Research
SN - 0250-7005
IS - 12
ER -